AUTOLUS THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.8 USD | -0.83% |
|
-9.94% | -25.47% |
Financials (USD)
| Sales 2024 * | 30.47M | Sales 2025 * | 71.52M | Capitalization | 1.28B |
|---|---|---|---|---|---|
| Net income 2024 * | -174M | Net income 2025 * | -127M | EV / Sales 2024 * | 19.7 x |
| Net cash position 2024 * | 678M | Net cash position 2025 * | 585M | EV / Sales 2025 * | 9.67 x |
| P/E ratio 2024 * |
-6.07
x | P/E ratio 2025 * |
-9.16
x | Employees | 467 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Autolus Therapeutics plc
More recommendations
More press releases
| 1 day | -0.83% | ||
| 1 week | -9.94% | ||
| Current month | -24.76% | ||
| 1 month | -22.64% | ||
| 3 months | -24.05% | ||
| 6 months | +89.72% | ||
| Current year | -25.47% |
1 week
4.79
5.25
1 month
4.796.63
Current year
4.797.45
1 year
1.617.45
3 years
1.608.23
5 years
1.6027.97
10 years
1.6053.24
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Pulé
FOU | Founder | 51 | 14-08-31 |
| Chief Executive Officer | 59 | 14-09-30 | |
Robert Dolski
DFI | Director of Finance/CFO | 54 | 23-08-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Berriman
BRD | Director/Board Member | 76 | 14-07-31 |
William Young
BRD | Director/Board Member | 79 | 21-11-14 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 4.8 | -0.83% | 1,211,739 |
| 24-04-17 | 4.84 | -0.41% | 788,189 |
| 24-04-16 | 4.86 | -0.82% | 612,013 |
| 24-04-15 | 4.9 | -2.39% | 788,744 |
| 24-04-12 | 5.02 | -5.82% | 1,494,300 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.8
USD
Average target price
10.54
USD
Spread / Average Target
+119.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.47% | 1.28B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.72% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- AUTL Stock
